Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Camrelizumab and Chemotherapy as Neoadjuvant Treatment for Locallyadvanced Esophageal Squamous Cell Carcinoma (Escc)a Single-Arm, Phase Ii Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PTPeng TangLGLei GongHZHongdian Zhang

Discussion

Loading...

Member takes

Overview

Phase II trial shows significant major pathological response in patients with advanced ESCC, suggesting immunotherapy's potential impact.

Key Points

  • Neoadjuvant treatment achieved a major pathological response rate of 67.6% in patients with ESCC.
  • Of 34 patients completing treatment, 17.6% had a pathological complete response, indicating efficacy in this population.
  • Analysis revealed that infiltrated lymphocyte levels were significantly lower in non-responders, affecting treatment outcomes.
  • Findings indicate that myeloid-derived suppressor cells may play a role in poor immunotherapy responses in ESCC.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b86bhttps://doi.org/10.1093/dote/doaf061.152
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025
  2. 2Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study2025 · 1 citations
  3. 3272. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS CONVERSION THERAPY FOR LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM STUDY2025
  4. 4287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY2025
  5. 5107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS2025